相关实验视频

Updated: Jul 10, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

特拉斯图祖马布德鲁克斯泰康用于脑转移性状肺癌与免疫相关的缺血炎:一个病例报告

Rui Xu¹, Jiadi Gan¹, Jiarui Zhang¹

¹Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Health, Center of Precision Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Frontiers in pharmacology

|September 29, 2025

概括

免疫疗法是第一线治疗肺状细胞癌 (LUSC),但不良反应可能会停止治疗. 像Trastuzumab Deruxte这样的抗体药物联合体 (ADC) 可以为无法继续免疫治疗的HER2突变患者提供替代方案.

科学领域:

在瘤学瘤学.
医学遗传学医学遗传学

背景情况:

免疫疗法是肺状细胞癌 (LUSC) 的标准一线治疗方法.
由于不良反应而停止免疫治疗需要使用替代治疗策略.
在某些LUSC病例中,HER2突变是可采取行动的目标.

研究的目的:

为了呈现一种脑转移性LUSC病例与HER2突变.
突出抗体 - 药物合物 (ADC) 在LUSC患者经历免疫治疗相关不良事件的潜力.
评估Trastuzumab Deruxtecan (T-DXd) 在LUSC和HER2突变不能耐受免疫治疗的患者的疗效.

主要方法:

一个LUSC患者的大脑转移和HER2突变的病例报告.
患者接受了免疫疗法,经历了低体质炎,随后停止了治疗.
在免疫治疗后开始使用Trastuzumab Deruxtecan (T-DXd) 治疗.

主要成果:

患有大脑转移性LUSC和HER2突变的患者在免疫治疗后出现了低血清炎.
特拉斯图祖马布德鲁克斯泰坎 (T-DXd) 治疗在这个患者中带来了临床益处.
患者在停止免疫治疗后可以很好地容忍T-DXd.

结论:

特拉斯图祖马布德鲁克斯坦 (T-DXd) 可能是HER2突变的LUSC患者的可行的替代治疗方法.
由于不良反应,T-DXd为无法继续免疫治疗的LUSC患者提供了潜在的治疗选择.
这一案例强调了针对性疗法 (如ADCs) 在管理具有特定突变的高级LUSC方面的重要性.

关键词:

抗体 - 药物联合体与免疫相关的不良事件.与免疫相关的低血压炎.免疫疗法免疫疗法有针对性的治疗.

更多相关视频

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...